Celcuity Inc.

MINNEAPOLIS, MN · Founded 2011 · Biotech · Public

Genomic/proteomic platform that identifies patient-specific oncogenic pathways to guide targeted cancer therapy development and patient stratification

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · celcuity.com

Sector: Biotech
Headquarters: MINNEAPOLIS, MN
Founded: 2011
Latest Form D: $50M, Oct 2023
Total capital: $185M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $185M; 9 Form D · last Oct 2023; 36 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 7; 16 pending · first 2021; Rank in peer group#33 of 342

Capital timeline

Latest events

Oct 2023Private capital raisedForm D · SEC · 9th filing$50M
May 2022Private capital raisedForm D · SEC · 8th filing$100M
Apr 2021Private capital raisedForm D · SEC · 7th filing$15M
Apr 2021Private capital raisedForm D · SEC · 6th filing$5M
May 2017Private capital raisedForm D · SEC · 5th filing$2.6M
May 2017Private capital raisedForm D · SEC · 4th filing$5.8M
Feb 2016Private capital raisedForm D · SEC · 3rd filing$325K
Dec 2015Private capital raisedForm D · SEC · 2nd filing$2.1M
Mar 2014Private capital raisedForm D · SEC · 1st filing$4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 342 peers

Line = median

Biotech · Platform

Granted patents#33 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Brian F. SullivanExecutive Officer, Director, PromoterNamed in SEC Form D filings
David F. DalveyDirectorNamed in SEC Form D filings
Lance G. LaingExecutive Officer, DirectorNamed in SEC Form D filings
Leo G. FurchtDirectorNamed in SEC Form D filings
Maureen G. CroninDirectorNamed in SEC Form D filings
Polly A. MurphyDirectorNamed in SEC Form D filings

Show all 9 people

Richard E. BullerDirectorNamed in SEC Form D filings
Richard J. NigonDirectorNamed in SEC Form D filings
Vicky G. HahneExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 23

Jun 25, 2026PendingMethods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAUSPTOApplication 19539411
Feb 26, 2026PendingTreatment Regimens For Gedatolisib In Hormonally-driven DisordersUSPTOApplication 19306599
Nov 13, 2025PendingMethods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAUSPTOApplication 19229722

Show all 23 patent records

Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAJun 25, 2026 · Application 19539411Pending
Treatment Regimens For Gedatolisib In Hormonally-driven DisordersFeb 26, 2026 · Application 19306599Pending
Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREANov 13, 2025 · Application 19229722Pending
Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAJul 8, 2025 · US 12,350,276Granted
Methods Of Measuring Signaling Pathway Activity For Selection Of Therapeutic AgentsJun 3, 2025 · US 12,320,799Granted
Methods Of Preparing A Primary Cell SampleFeb 4, 2025 · US 12,215,356Granted
Methods Of Preparing A Primary Cell SampleFeb 28, 2023 · US 11,591,573Granted
Methods Of Treating Cancer Patients With Ras Node Or Rtk Targeted Therapeutic AgentsDec 29, 2022 · Application 17835208Pending
Methods Of Measuring Signaling Pathway Activity For Selection Of Therapeutic AgentsMay 17, 2022 · US 11,333,659Granted
Assays And Methods For Determining The Responsiveness Of An Individual Subject To A Therapeutic AgentJul 27, 2021 · US 11,073,509Granted
Whole Cell Assays And MethodsJul 15, 2021 · Application 17193891Pending
Whole Cell Assays And MethodsApr 13, 2021 · US 10,976,307Granted
Methods Of Measuring Erbb Signaling Pathway Activity To Diagnose And Treat Cancer PatientsNov 30, 2017 · Application 15533897Pending
Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAApplication 63225707Pending
Treatment Regimens For Gedatolisib In Hormonally-driven DisordersApplication 63685556Pending
Methods Of Treating Cancer Patients With Ras Node Or Rtk Targeted Therapeutic AgentsApplication PCTUS2020063890Pending
Methods Of Treating Cancer Patients With PI3K Or Rtk Targeted Therapeutic AgentsApplication 62945608Pending
Methods For Treating Ocular Diseases Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAApplication PCTUS2024059586Pending
Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAApplication PCTUS2022038188Pending
Methods Of Measuring Signaling Pathway Activity For Selection Of Therapeutic AgentsApplication PCTUS2018022936Pending
Treatment Regimens For Gedatolisib In Hormonally-driven DisordersApplication PCTUS2025042990Pending
Methods For Treating Ocular Diseases Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAApplication 63609230Pending
Methods For The Treatment Of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREAApplication 63285327Pending

NewLimit, Inc.Similar federal contract value in Biotech · null in contracts
GondolaBioSimilar federal contract value in Biotech · null in contracts
BIOHARVEST SCIENCES INC.Similar federal contract value in Biotech · null in contracts
Areteia TherapeuticsSimilar federal contract value in Biotech · null in contracts
TRIANA BiomedicinesSimilar federal contract value in Biotech · null in contracts
Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.